Document is current
Any future updates will be listed below
-
Authors
Auclin, Edouard
Marthey, Lysiane
Abdallah, Raef
Mas, Léo
Francois, Eric
Saint, Angélique
Cunha, Antonio Sa
Vienot, Angélique
Lecomte, Thierry
Hautefeuille, Vincent
de La Fouchardière, Christelle https://orcid.org/0000-0003-2291-5693
Sarabi, Matthieu
Ksontini, Feryel
Forestier, Julien
Coriat, Romain
Fabiano, Emmanuelle
Leroy, Florence
Williet, Nicolas https://orcid.org/0000-0002-7296-5464
Bachet, Jean-Baptiste
Tougeron, David
Taieb, Julien https://orcid.org/0000-0002-9955-4753
- License Information
-
More Information
Article History
Received: 18 December 2020
Revised: 2 March 2021
Accepted: 4 March 2021
First Online: 26 March 2021
Ethics approval and consent to participate
: No informed consent was needed for this observational study, as stated by the French ethics committee consulted prior to the beginning of the work.
: Data are available from J.T. at reasonable request.
: E.A.: Travel expenses: Mundipharma. Lectures and educational activities: Sanofi Genzymes, Lilly-Oncology. J.T.: Consulting or advisory role: Roche, Merck KGaA, Darmstadt, Germany, Amgen, Celgene, Eli Lilly, Servier, Sirtex Medical, Merck Sharp & Dohme, Pierre Fabre. Speakers’ Bureau: Servier, Amgen, Roche/Genentech, Sanofi, Merck KGaA, Darmstadt, Germany, Eli Lilly, Merck Sharp & Dohme, Pierre Fabre. The other authors have nothing to declare.
: This study was not funded.
